GLP-3 R
Triple Incretin Receptor Agonism & Weight Reduction
What is GLP-3 R?
GLP-3 R on this reference site refers to a retatrutide-class research peptide — a triple incretin receptor agonist that targets the GLP-1, GIP, and glucagon (GcgR) receptors simultaneously. This three-way mechanism builds on single- and dual-agonist approaches by adding glucagon receptor activation, which research suggests may increase energy expenditure and enhance hepatic fat mobilization, in addition to the insulin-secretory, glucagon-suppressing, and appetite-modulating effects associated with GLP-1 and GIP signaling. The molecule is a 39-amino-acid engineered peptide.
A critical distinction: retatrutide is investigational and is NOT FDA approved. Unlike semaglutide and tirzepatide, whose reference drugs are already approved medicines, retatrutide remains in clinical development and has not received regulatory approval for any use. That said, published clinical trial data have drawn substantial attention, with reported average weight reductions in the approximate range of 24% to 28% of body weight at higher doses over the studied periods — among the largest figures observed in this compound class to date. Trials have also indicated improvements in lipid profiles and reductions in hepatic fat, though these findings require confirmation in larger, longer trials.
Because retatrutide is still investigational, its full efficacy and safety profile has not been established, and later-phase results will be needed before any firm clinical conclusions can be drawn. The triple-agonist concept is scientifically notable precisely because it tests whether adding glucagon receptor activity meaningfully improves metabolic outcomes, a question that ongoing research is actively evaluating. The GLP-3 R peptide referenced here is not an approved drug and is provided strictly for research and educational purposes only — it is not approved for human use, and nothing on this page should be interpreted as medical advice.
Molecular data
Mechanism of action
In preclinical research, GLP-3 R is associated with the following pathways and targets:
Research highlights
- Triple receptor agonism: GLP-1R + GIPR + GcgR simultaneously
- Highest weight reduction observed in Phase 2 clinical trials
- Increases energy expenditure via glucagon receptor activation
- Improves lipid profiles and reduces hepatic fat in studies
Frequently asked questions
Is retatrutide FDA approved?
No. Retatrutide is investigational and has not received FDA approval for any use. Unlike semaglutide and tirzepatide, whose reference drugs are approved, retatrutide remains in clinical development, and the GLP-3 R peptide here is for research only.
What does GLP-3 R (retatrutide) do?
It is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Research suggests the added glucagon receptor activity may raise energy expenditure and mobilize hepatic fat, alongside the insulin and appetite effects of GLP-1/GIP signaling.
How much weight loss has retatrutide shown?
Published trials have reported average reductions in the approximate range of 24-28% of body weight at higher doses. These findings are for an investigational drug and require confirmation in larger, longer studies.
How is retatrutide different from tirzepatide and semaglutide?
Semaglutide is a single GLP-1 agonist, tirzepatide is a dual GIP/GLP-1 agonist, and retatrutide adds glucagon receptor activity as a triple agonist. Research suggests each added receptor may increase metabolic effect.
Is the GLP-3 R research peptide safe for human use?
No. Retatrutide's safety profile is still under investigation and it is not approved. The GLP-3 R peptide sold here is strictly for research and educational purposes and is not intended for human consumption.
Source GLP-3 R at Purgo Labs
≥99% purity, third-party COA verification, and same-day fulfillment.
Shop GLP-3 R at Purgo Labs ↗Related compounds
For research and educational purposes only. GLP-3 R is not approved for human use by any regulatory authority, and nothing on this page constitutes medical advice, diagnosis, or treatment. Research findings referenced here are predominantly preclinical.